These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 16918445)

  • 1. Immunology of O-glycosylated proteins: approaches to the design of a MUC1 glycopeptide-based tumor vaccine.
    Hanisch FG; Ninkovic T
    Curr Protein Pept Sci; 2006 Aug; 7(4):307-15. PubMed ID: 16918445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of a MUC1-based cancer vaccine.
    Hanisch FG
    Biochem Soc Trans; 2005 Aug; 33(Pt 4):705-8. PubMed ID: 16042579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue.
    Gad M; Jensen T; Gagne R; Komba S; Daugaard S; Kroman N; Meldal M; Werdelin O
    Eur J Immunol; 2003 Jun; 33(6):1624-32. PubMed ID: 12778480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. O-Linked glycans control glycoprotein processing by antigen-presenting cells: a biochemical approach to the molecular aspects of MUC1 processing by dendritic cells.
    Hanisch FG; Schwientek T; Von Bergwelt-Baildon MS; Schultze JL; Finn O
    Eur J Immunol; 2003 Dec; 33(12):3242-54. PubMed ID: 14635032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes.
    Ninkovic T; Kinarsky L; Engelmann K; Pisarev V; Sherman S; Finn OJ; Hanisch FG
    Mol Immunol; 2009 Nov; 47(1):131-40. PubMed ID: 19007994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. O-glycosylated human MUC1 repeats are processed in vitro by immunoproteasomes.
    Ninkovic T; Hanisch FG
    J Immunol; 2007 Aug; 179(4):2380-8. PubMed ID: 17675499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
    Sørensen AL; Reis CA; Tarp MA; Mandel U; Ramachandran K; Sankaranarayanan V; Schwientek T; Graham R; Taylor-Papadimitriou J; Hollingsworth MA; Burchell J; Clausen H
    Glycobiology; 2006 Feb; 16(2):96-107. PubMed ID: 16207894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice.
    Ryan SO; Vlad AM; Islam K; Gariépy J; Finn OJ
    Biol Chem; 2009 Jul; 390(7):611-8. PubMed ID: 19426130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell recognition of tumor-associated carbohydrates: the nature of the glycan moiety plays a decisive role in determining glycopeptide immunogenicity.
    Galli-Stampino L; Meinjohanns E; Frische K; Meldal M; Jensen T; Werdelin O; Mouritsen S
    Cancer Res; 1997 Aug; 57(15):3214-22. PubMed ID: 9242452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.
    Lakshminarayanan V; Thompson P; Wolfert MA; Buskas T; Bradley JM; Pathangey LB; Madsen CS; Cohen PA; Gendler SJ; Boons GJ
    Proc Natl Acad Sci U S A; 2012 Jan; 109(1):261-6. PubMed ID: 22171012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma.
    Stepensky D; Tzehoval E; Vadai E; Eisenbach L
    Clin Exp Immunol; 2006 Jan; 143(1):139-49. PubMed ID: 16367945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells.
    Vlad AM; Muller S; Cudic M; Paulsen H; Otvos L; Hanisch FG; Finn OJ
    J Exp Med; 2002 Dec; 196(11):1435-46. PubMed ID: 12461079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MUC1 glycopeptide epitopes predicted by computational glycomics.
    Song W; Delyria ES; Chen J; Huang W; Lee JS; Mittendorf EA; Ibrahim N; Radvanyi LG; Li Y; Lu H; Xu H; Shi Y; Wang LX; Ross JA; Rodrigues SP; Almeida IC; Yang X; Qu J; Schocker NS; Michael K; Zhou D
    Int J Oncol; 2012 Dec; 41(6):1977-84. PubMed ID: 23023583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microarray Analysis of Antibodies Induced with Synthetic Antitumor Vaccines: Specificity against Diverse Mucin Core Structures.
    Pett C; Cai H; Liu J; Palitzsch B; Schorlemer M; Hartmann S; Stergiou N; Lu M; Kunz H; Schmitt E; Westerlind U
    Chemistry; 2017 Mar; 23(16):3875-3884. PubMed ID: 27957769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure/activity studies of the anti-MUC1 monoclonal antibody C595 and synthetic MUC1 mucin-core-related peptides and glycopeptides.
    Spencer DI; Missailidis S; Denton G; Murray A; Brady K; Matteis CI; Searle MS; Tendler SJ; Price MR
    Biospectroscopy; 1999; 5(2):79-91. PubMed ID: 10217327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epitopes of MUC1 Tandem Repeats in Cancer as Revealed by Antibody Crystallography: Toward Glycopeptide Signature-Guided Therapy.
    Zhou D; Xu L; Huang W; Tonn T
    Molecules; 2018 May; 23(6):. PubMed ID: 29857542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response.
    Madsen CB; Petersen C; Lavrsen K; Harndahl M; Buus S; Clausen H; Pedersen AE; Wandall HH
    PLoS One; 2012; 7(11):e50139. PubMed ID: 23189185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of α-S-Neoglycopeptides Derived from MUC1 with a Flexible and Solvent-Exposed Sugar Moiety.
    Rojas-Ocáriz V; Compañón I; Aydillo C; Castro-Loṕez J; Jiménez-Barbero J; Hurtado-Guerrero R; Avenoza A; Zurbano MM; Peregrina JM; Busto JH; Corzana F
    J Org Chem; 2016 Jul; 81(14):5929-41. PubMed ID: 27305427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist.
    Abdel-Aal AB; Lakshminarayanan V; Thompson P; Supekar N; Bradley JM; Wolfert MA; Cohen PA; Gendler SJ; Boons GJ
    Chembiochem; 2014 Jul; 15(10):1508-13. PubMed ID: 24890740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat.
    Tarp MA; Sørensen AL; Mandel U; Paulsen H; Burchell J; Taylor-Papadimitriou J; Clausen H
    Glycobiology; 2007 Feb; 17(2):197-209. PubMed ID: 17050588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.